For intracranial artery stenosis patients, high inter-individual variability in response to antiplatelet drug therapy results in recurrent ischemic events. We aimed to evaluate the association of drug-related genetic polymorphisms with adverse clinical outcomes. We consecutively enrolled 157 patients receiving dual-antiplatelet therapy (aspirin plus clopidogrel), and adverse clinical events occurred in 10 patients during the one year follow-up. The P2Y12 polymorphisms (rs9859538 and rs10935842) were associated with increased likelihood of relapse events (OR=2.934, 95%CI=1.022-8.425, P-value=0.045), and the two variants are in complete linkage disequilibrium. The mutation of ABCB1 rs1128503 may decrease the recurrence of clinical events (OR=0.211, 95%CI=0.046-0.957, P-value=0.044). Genetic testing (ABCB1 and P2Y12) may provide useful information to prevent ischemic events prior to the initiation of antiplatelet therapy. This article is protected by copyright. All rights reserved.
Keywords: ABCB1; P2Y12; ischemic stroke; polymorphism.
This article is protected by copyright. All rights reserved.